861960-34-1

Basic information

• Product Name: 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE
• Synonyms: 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE;7-Methoxy-3,4dihydro-1-naphthalenylaccetonitrile;3,4-Dihydro-7-Methoxy-1-naphthaleneacetonitrile;(7-Methoxy-3,4-dihydro-1-naphthyl)acetonitrile;2-(7-Methoxy-3,4-dihydronaphthalen-1-yl)acetonitrile;7-Methoxy-3,4-Dihydro-1-Naphthalenyl-acetonitrile 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE
• CAS NO: 861960-34-1
• Molecular Formula: C₁₃H₁₃NO
• Molecular Weight: 199.24842
• Product Categories: Aromatics Compounds;Aromatics;Intermediate of Agomelatine
• Mol File: 861960-34-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 41-43°C
• Boiling Point: 349.603 °C at 760 mmHg
• Flash Point: 147.517 °C
• Appearance: /
• Density: 1.092 g/cm³
• Vapor Pressure: 0.001Pa at 25℃
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE(861960-34-1)
• EPA Substance Registry System: 7-METHOXY-3,4-DIHYDRO-1-NAPHTHALENYL-ACETONITRILE(861960-34-1)

Safety Data

• Hazardous Substances Data: 861960-34-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

7-Methoxy-3,4-dihydro-1-naphthalenyl-acetonitrile (cas# 861960-34-1) is a compound useful in organic synthesis.

Upstream product

• 6836-19-7 7-Methoxy-1-tetralone 
• 372-09-8 cyanoacetic acid 
• 2537-48-6 diethyl 1-cyanomethylphosphonate 
• 100-66-3 methoxybenzene 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 138113-08-3 (7-methoxy-1-naphthyl)acetonitrile 

Downstream Products

• 138113-08-3 (7-methoxy-1-naphthyl)acetonitrile 
• 1353428-89-3 2-(7-methoxy-3,4-dihydro-1-naphthyl)ethylamine 
• 1353100-18-1 2-(7-methoxy-3,4-dihydro-naphthalene-1-yl)-ethylamine hydrochloride 
• 1352139-51-5 N-[2-(7-methoxy-3,4-dihydro-naphthalen-1-yl)ethyl]acetamide 
• 138112-76-2 agomelatine 
• 139525-77-2 2-(7-methoxynaphthalen-1-yl)ethanamine hydrochloride 

Relevant articles and documents

Preparation method of agomelatine intermediate

The invention relates to a preparation method of an agomelatine intermediate. Specifically, the invention provides a preparation method of an agomelatine important intermediate 2-(7-methoxy-1-naphthyl)acetonitrile II, 7-methoxy-1-tetralone is used as an initial raw material, condensation and oxidation reactions are carried out to obtain the intermediate 2-(7-methoxy-1-naphthyl)acetonitrile, and the preparation method has the advantages of good yield, high product purity, simple reaction and easy operation, and is suitable for industrial production .

Preparation method of 7-methoxy-1-naphthylacetonitrile

The invention discloses a preparation method of 7-methoxy-1-naphthylacetonitrile, which is characterized by comprising the following steps of adding 7-methoxy-3, 4-dihydro-1-naphthylacetonitrile intoa first solvent, dissolving, adding allyl methacrylate, uniformly stirring, adding a catalyst ruthenium/carbon, and carrying out dehydrogenation aromatization reaction, and after the reaction is finished, filtering out the catalyst, desolventizing the filtrate under reduced pressure, adding a second solvent, heating to dissolve, cooling, crystallizing, carrying out suction filtration, and drying to obtain the white crystal 7-methoxy-1-naphthylacetonitrile. The preparation method of 7-methoxy-1-naphthylacetonitrile provided by the invention is simple to operate, less in pollution, low in cost,high in yield, less in side reaction and high in product purity, and the catalyst can be repeatedly used.

Naphthalene derivatives and their application on the medicament

The invention provides a number of naphthalene derivatives or stereoisomers, tautomers, nitrogen oxides, metabolites, pharmaceutically acceptable salts or prodrugs thereof which are used for excitement of melatonin receptors. The invention also discloses pharmaceutical compositions containing such compounds and application thereof in treatment of central nervous system dysfunction of mammals, especially human.